Industry
Biotechnology
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 3:07 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 10:37 am
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 8:18 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 11:12 am
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 12:56 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 10:50 am
Portfolio Pulse from Avi Kapoor
March 14, 2024 | 12:57 pm
Portfolio Pulse from Benzinga Newsdesk
March 08, 2024 | 7:52 am
Portfolio Pulse from Benzinga Newsdesk
March 06, 2024 | 7:33 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.